Internet Explorer 8 Warnung Anscheinend verwenden Sie einen älteren Internet Explorer. Leider unterstützen wir, genau wie Microsoft, diesen Browser nicht mehr. Sie werden also Fehlermeldungen und ein inkonsistentes Design erleben.
Bitte haben Sie Verständnis und entschuldigen Sie die Unannehmlichkeiten.
Logo HTGF

News

Noscendo closes Financing Round for CE Certification and Market Entry Preparation of Platform Diagnostics for Bloodstream Associated Infections

The diagnostic procedures developed by Noscendo help intensive care clinicians to identify the relevant pathogens in bloodstream associated infections. Munich-based family office Wieland Capital, HTGF and three business angels with in-depth knowledge of the diagnostics industry are jointly investing a seven-digit sum of Euros into Noscendo GmbH. These funds will enable Noscendo to receive approval for its medical device and prepare for the market entry of Noscendo’s proprietary diagnostic platform.

In two-thirds of all cases, existing diagnostic procedures do not allow intensive care clinicians to draw conclusions on the pathogens causing bloodstream associated infections such as sepsis (“blood poisoning”) and endocarditis (inflammation of the inner layers of the heart). Therapy options are therefore very often limited to administering broad-band antibiotics. Unspecific therapy leads to high mortality rates and severe complications in many patients, and also accentuates the issue of resistant hospital pathogens.

Noscendo identifies bacteria, fungi, viruses and parasites in the patient’s bloodstream via Next Generation Sequencing (NGS) and is able to assess the relevance of each pathogen using proprietary algorithms. In poly-microbial infections, the diagnostic platform differentiates the primary pathogen(s) across various pathogen classes. Using Noscendo’s analytical results, intensive care clinicians can treat patients much more specifically by administering the most effective therapeutic drug according to the identified relevant pathogen.

“We are absolutely delighted to have won over a powerful consortium of investors in the form of Wieland Capital as lead investor, HTGF, and three highly experienced business angels, who will be a great support in further developing our approach”, says Dr. Philip Stevens, CEO of Noscendo. Robert Wieland, Managing Director of the Munich-based family office Wieland Capital, strongly believes in the tech­no­logy: “Noscendo’s diagnostic platform for analysis and identification of pathogens provides far more precise and reliable results and has the potential to define a new gold standard in intensive care”.

Financial resources from the investment round will be utilized for CE certification of Noscendo’s diagnostic platform as a medical device (“Software as a Medical Device”) and preparation for market entry. “Together with innovative intensive care clinicians and sophisticated partners, we will introduce our diagnostic services as a mail-in business as well as on-site in selected hospital laboratories,” Dr. Peter Haug, CEO and Head of Business Development, explains the next steps towards market entry.

“The excellent feedback from clinical directors and the huge experience of the team and the business angels provide ideal conditions for Noscendo to set a new standard in the pathogen detection of life-threatening blood stream infections”, Dr. Fabian Mohr summarizes HTGF’s viewpoint.

About Noscendo GmbH
Noscendo GmbH develops bioinformatic solutions to identify and assess pathogens in bloodstream associated and related infections. The proprietary diagnostic platform has been validated together with leading German clinicians and will be provided in the area of bloodstream infections. For this, Noscendo works together with leading hospitals, development partners, logistics providers, innovation-driven health service providers and health insurance funds.

Contact
Noscendo GmbH
Dr. Philip Stevens
Königstrasse 34
47198 Duisburg
Phone: +49 (0)2066-5068780
Email: info@noscendo.com
www.noscendo.com

About Wieland Capital
Wieland Capital is a family office with a focus on direct entrepreneurial participations, especially in the healthcare sector.

Contact
Robert Wieland
Phone: +49 (0)89 4161 933 0
Email: info@wieland-capital.com

About High-Tech Gründerfonds
High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven start-ups. With EUR 892.5 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge 500 start-ups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and start-up experts help guide the development of young companies. HTGF’s focus is on high-tech start-ups in a range of sectors, including software, hardware and life sciences / chemistry.
This group also includes a number of success stories, such as Mister Spex, Rigontec, 6Wunderkinder, Next Kraftwerke and Cumulocity, as well as Juniqe, an online shop for art enthusiasts. To date, external investors have injected over EUR 1.9 billion into the HTGF portfolio via about 1,400 follow-on financing rounds. HTGF has also successfully sold interests by now 100 companies. Investors in this public-private partnership include the Federal Ministry For Economic Affairs and Energy, the KfW Banking Group, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA, BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, BÜFA, CEWE, Deutsche Post DHL, Dräger, Drillisch AG, EVONIK, EWE AG, Haniel, Hettich, Knauf, Körber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, Postbank, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Thüga, Vector Informatik, WACKER and Wilh. Werhahn KG.

Contact
High-Tech Gründerfonds Management GmbH
Dr. Fabian Mohr
Schlegelstraße 2
53113 Bonn / Germany
T: +49 228 82300 181
f.mohr@htgf.de
www.htgf.de